<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909804</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-342-0109</org_study_id>
    <nct_id>NCT01909804</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects With Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the antiviral efficacy, safety, and
      tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV)
      in treatment-naive adults with chronic genotype (GT) 1 or 3 hepatitis C virus (HCV)
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <description>SVR4 and SVR 24 were defined as HCV RNA &lt; LLOQ at 4 and 24 weeks after stopping study treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg (GT3) without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg (GT3) without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg (GT3) with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg (GT3) with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF</intervention_name>
    <description>400 mg tablet administered orally once daily</description>
    <arm_group_label>SOF+VEL 25 mg (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT1)</arm_group_label>
    <other_name>Sovaldi®</other_name>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEL</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>SOF+VEL 25mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT1)</arm_group_label>
    <other_name>GS-5816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>SOF+VEL 25mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) without cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT3) with cirrhosis</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg+RBV (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg+RBV (GT1)</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥ 18 kg/m^2

          -  HCV RNA ≥ 10000 IU/mL at screening

          -  Prior treatment failure to a regimen including interferon with or without RBV

          -  HCV genotype 1 or 3

          -  Chronic HCV infection

          -  Cirrhosis determination

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Current or prior history of clinically significant illness other than HCV

          -  Screening ECG with clinically significant abnormalities

          -  Prior exposure to HCV specific direct acting antiviral agent

          -  Pregnant or nursing female or male with pregnant female partner

          -  Chronic liver disease of non-HCV etiology

          -  Hepatitis B

          -  Active drug abuse

          -  Use of any prohibited concomitant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McNally</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. High Efficacy of Treatment with Sofosbuvir+GS-5816±Ribavirin for 12 Weeks in Treatment-Experienced Patients with Genotype 1 or 3 HCV Infection [Abstract 197]. American Association for the Study of Liver Diseases (AASLD); 2014 November 7-11; Boston MA United States.</citation>
  </results_reference>
  <results_reference>
    <citation>Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10.</citation>
    <PMID>26551263</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <results_first_submitted>July 27, 2016</results_first_submitted>
  <results_first_submitted_qc>July 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2016</results_first_posted>
  <disposition_first_submitted>January 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2015</disposition_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Genotype 3</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in Australia, New Zealand, and the United States. The first participant was screened on 17 June 2013. The last study visit occurred on 22 August 2014.</recruitment_details>
      <pre_assignment_details>416 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SOF+VEL 25 mg (GT3 Non-Cirrhotic)</title>
          <description>Sofosbuvir (SOF) 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype (GT) 3 non-cirrhotic)</description>
        </group>
        <group group_id="P2">
          <title>SOF+VEL 25 mg + RBV (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + velpatasvir (VEL) 25 mg tablet administered orally once daily + ribavirin (RBV) tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
        </group>
        <group group_id="P3">
          <title>SOF+VEL 100 mg (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 non-cirrhotic)</description>
        </group>
        <group group_id="P4">
          <title>SOF+VEL 100 mg + RBV (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
        </group>
        <group group_id="P5">
          <title>SOF+VEL 25 mg (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="P6">
          <title>SOF+VEL 25 mg + RBV (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="P7">
          <title>SOF+VEL 100 mg (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="P8">
          <title>SOF+VEL 100 mg + RBV (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="P9">
          <title>SOF+VEL 25 mg (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="P10">
          <title>SOF+VEL 25 mg + RBV (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="P11">
          <title>SOF+VEL 100 mg (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="P12">
          <title>SOF+VEL 100 mg + RBV (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="26"/>
                <participants group_id="P9" count="27"/>
                <participants group_id="P10" count="29"/>
                <participants group_id="P11" count="27"/>
                <participants group_id="P12" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="27"/>
                <participants group_id="P10" count="28"/>
                <participants group_id="P11" count="26"/>
                <participants group_id="P12" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>SOF+VEL 25 mg (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype (GT) 3 non-cirrhotic)</description>
        </group>
        <group group_id="B2">
          <title>SOF+VEL 25 mg + RBV (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
        </group>
        <group group_id="B3">
          <title>SOF+VEL 100 mg (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 non-cirrhotic)</description>
        </group>
        <group group_id="B4">
          <title>SOF+VEL 100 mg + RBV (GT3 Non-Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
        </group>
        <group group_id="B5">
          <title>SOF+VEL 25 mg (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="B6">
          <title>SOF+VEL 25 mg + RBV (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="B7">
          <title>SOF+VEL 100 mg (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="B8">
          <title>SOF+VEL 100 mg + RBV (GT3 Cirrhotic)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
        </group>
        <group group_id="B9">
          <title>SOF+VEL 25 mg (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="B10">
          <title>SOF+VEL 25 mg + RBV (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="B11">
          <title>SOF+VEL 100 mg (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="B12">
          <title>SOF+VEL 100 mg + RBV (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="25"/>
            <count group_id="B7" value="26"/>
            <count group_id="B8" value="26"/>
            <count group_id="B9" value="27"/>
            <count group_id="B10" value="29"/>
            <count group_id="B11" value="27"/>
            <count group_id="B12" value="28"/>
            <count group_id="B13" value="321"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11.8"/>
                    <measurement group_id="B2" value="51" spread="10.4"/>
                    <measurement group_id="B3" value="55" spread="6.9"/>
                    <measurement group_id="B4" value="56" spread="6.4"/>
                    <measurement group_id="B5" value="57" spread="7.0"/>
                    <measurement group_id="B6" value="56" spread="5.6"/>
                    <measurement group_id="B7" value="56" spread="5.7"/>
                    <measurement group_id="B8" value="54" spread="4.7"/>
                    <measurement group_id="B9" value="55" spread="8.1"/>
                    <measurement group_id="B10" value="57" spread="5.8"/>
                    <measurement group_id="B11" value="57" spread="6.4"/>
                    <measurement group_id="B12" value="56" spread="6.0"/>
                    <measurement group_id="B13" value="55" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="10"/>
                    <measurement group_id="B13" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="22"/>
                    <measurement group_id="B11" value="15"/>
                    <measurement group_id="B12" value="18"/>
                    <measurement group_id="B13" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="25"/>
                    <measurement group_id="B10" value="28"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="27"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="21"/>
                    <measurement group_id="B13" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Genotype 1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="22"/>
                    <measurement group_id="B11" value="21"/>
                    <measurement group_id="B12" value="22"/>
                    <measurement group_id="B13" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1 (no confirmed subtype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28b Status</title>
          <description>CC, CT, and TT alleles are different forms of the IL28b gene.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="21"/>
                    <measurement group_id="B11" value="17"/>
                    <measurement group_id="B12" value="19"/>
                    <measurement group_id="B13" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cirrhosis Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="17"/>
                    <measurement group_id="B10" value="19"/>
                    <measurement group_id="B11" value="18"/>
                    <measurement group_id="B12" value="18"/>
                    <measurement group_id="B13" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="10"/>
                    <measurement group_id="B13" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="0.76"/>
                    <measurement group_id="B2" value="6.6" spread="0.70"/>
                    <measurement group_id="B3" value="6.6" spread="0.59"/>
                    <measurement group_id="B4" value="6.7" spread="0.53"/>
                    <measurement group_id="B5" value="6.6" spread="0.46"/>
                    <measurement group_id="B6" value="6.2" spread="0.68"/>
                    <measurement group_id="B7" value="6.4" spread="0.76"/>
                    <measurement group_id="B8" value="6.7" spread="0.51"/>
                    <measurement group_id="B9" value="6.5" spread="0.59"/>
                    <measurement group_id="B10" value="6.8" spread="0.37"/>
                    <measurement group_id="B11" value="6.4" spread="0.53"/>
                    <measurement group_id="B12" value="6.5" spread="0.43"/>
                    <measurement group_id="B13" value="6.6" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="29"/>
                    <measurement group_id="B11" value="24"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior HCV Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapse / Breakthrough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="16"/>
                    <measurement group_id="B11" value="20"/>
                    <measurement group_id="B12" value="20"/>
                    <measurement group_id="B13" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</title>
        <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 12</time_frame>
        <population>Full Analysis Set: participants randomized into the study and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype (GT) 3 non-cirrhotic)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 25 mg + RBV (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 100 mg (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg + RBV (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 25 mg (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 25 mg + RBV (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O7">
            <title>SOF+VEL 100 mg (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O8">
            <title>SOF+VEL 100 mg + RBV (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O9">
            <title>SOF+VEL 25 mg (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O10">
            <title>SOF+VEL 25 mg + RBV (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O11">
            <title>SOF+VEL 100 mg (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O12">
            <title>SOF+VEL 100 mg + RBV (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</title>
          <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
          <population>Full Analysis Set: participants randomized into the study and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="26"/>
                <count group_id="O9" value="27"/>
                <count group_id="O10" value="29"/>
                <count group_id="O11" value="27"/>
                <count group_id="O12" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O2" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                    <measurement group_id="O5" value="57.7" lower_limit="36.9" upper_limit="76.6"/>
                    <measurement group_id="O6" value="84.0" lower_limit="63.9" upper_limit="95.5"/>
                    <measurement group_id="O7" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O8" value="96.2" lower_limit="80.4" upper_limit="99.9"/>
                    <measurement group_id="O9" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O10" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O11" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O12" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</title>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotypes 1 and 3)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 25 mg + RBV</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotypes 1 and 3)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 100 mg</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotypes 1 and 3)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg + RBV</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotypes 1 and 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</title>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
        <description>SVR4 and SVR 24 were defined as HCV RNA &lt; LLOQ at 4 and 24 weeks after stopping study treatment, respectively.</description>
        <time_frame>Posttreatment Weeks 4 and 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype (GT) 3 non-cirrhotic)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 25 mg + RBV (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 100 mg (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg + RBV (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 25 mg (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 25 mg + RBV (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O7">
            <title>SOF+VEL 100 mg (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O8">
            <title>SOF+VEL 100 mg + RBV (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O9">
            <title>SOF+VEL 25 mg (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O10">
            <title>SOF+VEL 25 mg + RBV (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O11">
            <title>SOF+VEL 100 mg (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O12">
            <title>SOF+VEL 100 mg + RBV (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
          <description>SVR4 and SVR 24 were defined as HCV RNA &lt; LLOQ at 4 and 24 weeks after stopping study treatment, respectively.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="26"/>
                <count group_id="O9" value="27"/>
                <count group_id="O10" value="29"/>
                <count group_id="O11" value="27"/>
                <count group_id="O12" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O2" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                    <measurement group_id="O5" value="61.5" lower_limit="40.6" upper_limit="79.8"/>
                    <measurement group_id="O6" value="84.0" lower_limit="63.9" upper_limit="95.5"/>
                    <measurement group_id="O7" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O8" value="96.2" lower_limit="80.4" upper_limit="99.9"/>
                    <measurement group_id="O9" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O10" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O11" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O12" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O2" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                    <measurement group_id="O5" value="57.7" lower_limit="36.9" upper_limit="76.6"/>
                    <measurement group_id="O6" value="84.0" lower_limit="63.9" upper_limit="95.5"/>
                    <measurement group_id="O7" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                    <measurement group_id="O8" value="96.2" lower_limit="80.4" upper_limit="99.9"/>
                    <measurement group_id="O9" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O10" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O11" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O12" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Failure</title>
        <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
        <time_frame>Up to Posttreatment Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype (GT) 3 non-cirrhotic)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 25 mg + RBV (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 100 mg (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg + RBV (GT3 Non-Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 non-cirrhotic)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 25 mg (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 25 mg + RBV (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O7">
            <title>SOF+VEL 100 mg (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O8">
            <title>SOF+VEL 100 mg + RBV (GT3 Cirrhotic)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 3 cirrhotic)</description>
          </group>
          <group group_id="O9">
            <title>SOF+VEL 25 mg (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O10">
            <title>SOF+VEL 25 mg + RBV (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O11">
            <title>SOF+VEL 100 mg (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O12">
            <title>SOF+VEL 100 mg + RBV (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotype 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Failure</title>
          <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="26"/>
                <count group_id="O9" value="27"/>
                <count group_id="O10" value="29"/>
                <count group_id="O11" value="27"/>
                <count group_id="O12" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="42.3"/>
                    <measurement group_id="O6" value="12.0"/>
                    <measurement group_id="O7" value="11.5"/>
                    <measurement group_id="O8" value="3.8"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3.4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks plus 30 days</time_frame>
      <desc>Safety Analysis Set</desc>
      <group_list>
        <group group_id="E1">
          <title>SOF+VEL 25 mg</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotypes 1 and 3)</description>
        </group>
        <group group_id="E2">
          <title>SOF+VEL 25 mg + RBV</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotypes 1 and 3)</description>
        </group>
        <group group_id="E3">
          <title>SOF+VEL 100 mg</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotypes 1 and 3)</description>
        </group>
        <group group_id="E4">
          <title>SOF+VEL 100 mg + RBV</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks (genotypes 1 and 3)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>May-Thurner syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

